Powered by: Motilal Oswal
2026-08-07 11:07:02 am | Source: Motilal Oswal Financial Services Ltd
Buy Inventurus Knowledge Solutions Ltd for the Target Rs 2,075 by Motilal Oswal Financial Services Ltd
Buy Inventurus Knowledge Solutions Ltd for the Target Rs 2,075 by Motilal Oswal Financial Services Ltd

Revenue in line; miss on margin and PAT

Inventurus Knowledge Solutions’ (IKS) 1QFY27 USD revenue was up 12% YoY at USD97m (est. USD97m). INR revenue rose 21% YoY to INR8.9b (est. INR8.1b), with EBITDA of INR2.9b (est. INR3.1b) and margin of 33.0%, up 24% YoY (est. 35%), led by strong traction in top accounts. EBITDA margin was impacted by Trubridge acquisition-related costs. Adjusted margin was ~35% (flat QoQ and in line with estimate). PAT at INR1.9b was up 28% YoY (est. INR2.1b). The miss was mainly due to a slightly higher tax rate and lower EBITDA amid acquisition-related costs. We expect a CAGR of 17%/19%/20% in organic revenue/EBITDA/PAT over FY26-28. We value the stock at 34x FY28E EPS to arrive at a TP of INR2,075 and reiterate our BUY rating on the stock.

Our view: US healthcare cost pressure remains a structural tailwind

* Management reiterated that IKS is evolving from a healthcare outsourcing company into an AI-enabled healthcare operating platform by combining workflow automation (System of Action) with electronic health records (System of Record) through the Trubridge acquisition.

* Trubridge acquisition was transformational rather than just revenueaccretive. It gives IKS access to over 2,100 rural and community hospitals, expands its addressable market, and enables cross-selling of its existing solutions into Trubridge's customer base.

* Focus remains on developing proprietary healthcare-specific AI models.

* Management reaffirmed its FY30 EBITDA target of INR30b, with minimal equity dilution and a return to pre-acquisition leverage levels.

* Management expects organic business to outperform the industry’s outsourcing growth rate (~12%).

* After completing the acquisition, management revised Trubridge's expected annual revenue to ~USD300m from the earlier estimate of USD340m.

* Combined EBITDA margins are expected to moderate to 26-27% in the near term.

Key deal wins

* Strategic partnership with premier integrated health system in California for a comprehensive clinical data migration for an acquired hospital

* Reuniting with one of the leaders in musculoskeletal space; this collaboration focuses on modernizing end-to-end RCM functions

* Advocate Health, an existing client expanding its partnership across RCM, including coding in volume and value efforts across its entire network in the acute and ambulatory space

* StrideCare, an existing client, extended RCM services for its acquired business (deals largely come from land and expand approach)

 

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here